PAIN TRIGGERS
ADHD medication loses its effectiveness over time or after a disruption in usage.
SaaS· adults with ADHDPain 7.00/10WTP 5.0/10Market 7.0/10Validation 8.0Confidence 95%Aug 19, 2026
ADHDMedTracker: Tolerance & Efficacy Tracking Protocol for Treatment-Resistant Adults
Previously effective ADHD medication (Vyvanse) has completely stopped working despite increasing to the maximum dosage, leading to a severe decline in functioning, life performance, and mental health.
analyticshealthcaremobile-appmonitoringproductivitysaasworkflow
1
STAGE 01 · PROBLEM
Is the problem real?
CANONICAL PROBLEM
Previously effective ADHD medication (Vyvanse) has completely stopped working despite increasing to the maximum dosage, leading to a severe decline in functioning, life performance, and mental health.
FREQUENCY
Multiple repeated complaints in the post and comments.
INTENSITY
Users explicitly describe existing tools as bloated/overkill and mention workaround behavior.
EVIDENCE
I want to feel better. Should I switch meds?
ADHD23
I want to feel better. Should I switch meds?
ADHD23
I want to feel better. Should I switch meds?
ADHD23
2
STAGE 02 · CUSTOMER
Who feels this pain?
TARGET USERS
adults with ADHDAdult A D H D Treatment Seekers
Adults struggling with chronic ADHD management whose stimulant medications have abruptly stopped working, leaving them unable to function.
Context
Find a medication or treatment strategy that effectively restores daily functioning, productivity, and mental well-being for ADHD management.
Slowly increasing the daily medication dose to the maximum limit to attempt to recapture therapeutic effects.
Switching between generic and brand-name versions of the same drug to troubleshoot reduced effectiveness.
Current Workarounds
slowly increasing the daily medication dose to the maximum limit
switching between generic and brand-name versions of the same drug
taking regular weekend breaks from medication in an attempt to manage tolerance
3
STAGE 03 · MARKET
Where's the gap?
EXISTING SOLUTION GAPS
Increasing the dosage of Vyvanse up to the maximum limit (70mg) fails to restore its effectiveness.
Switching from generic back to brand-name medication yields no improvement in symptoms.
Taking routine weekend tolerance breaks does not reset the efficacy of the drug.
OPPORTUNITY & VALUE
Why Now
Repeated complaints about ADHD medication losing its effectiveness over time or after usage interruptions.
Value Proposition
Purpose-built specifically for stimulant tolerance and drug-failure troubleshooting rather than basic habit tracking.
Product Direction
A structured tracking and clinical data-preparation application that logs daily stimulant efficacy, lifestyle/hormonal/sleep variables, and tolerance patterns to help patients and psychiatrists make evidence-based switches or holiday schedules.
4
STAGE 04 · BUSINESS
How does it make money?
MONETIZATION
$9/moIndividual monthly subscription
Model
SaaS subscription
WILLINGNESS TO PAY
Users express severe life distress and are already spending significant money on brand-name prescriptions and specialist visits without results; $9/mo is a low barrier to regain functional productivity.
5
STAGE 05 · EXECUTION
How do you ship it?
MVP PLAN
“From medication guesswork to data-backed clinical adjustments.”
A structured tracking and clinical data-preparation application that logs daily stimulant efficacy, lifestyle/hormonal/sleep variables, and tolerance patterns to help patients and psychiatrists make evidence-based switches or holiday schedules.
Core Features
Daily executive function and medication efficacy score logging
Sleep, nutrition, and hormonal variable tracker
Exportable clinical summary report for psychiatrist appointments
Weekly Roadmap
1
W1-W2
Core daily logging for medication efficacy and executive function is functional.
- •Design minimal daily check-in interface
- •Implement secure local and cloud data storage
- •Build baseline efficacy scoring algorithm
2
W3-W4
Variable correlation and psychiatrist report export are operational.
- •Build sleep and lifestyle factor logging
- •Develop PDF summary report generator for doctor visits
- •Add historical trend visualization graphs
3
W5
Billing integration and private beta launch with 10 users.
- •Integrate Stripe subscription processing
- •Recruit 10 beta testers from adult ADHD communities
- •Refine UI based on early user friction feedback
4
W6
Public release and initial user acquisition.
- •Publish landing page detailing clinical reporting features
- •Share tool value proposition within relevant support communities
- •Monitor initial subscription conversions
Launch Strategy
Target online ADHD communities on Reddit (r/ADHD) and specialized mental health support forums.
RISKS & ASSUMPTIONS
Top Risks
Medical advice liability
Users might interpret tracking insights as medical prescriptions, creating regulatory and legal liability.
High churn during executive dysfunction
When ADHD symptoms spike and functioning collapses, users often abandon tracking apps precisely when they need them most.
Value perception vs free note-taking
Users may choose to track symptoms in a basic notes app rather than pay for a dedicated tool.
6
STAGE 06 · DECISION
Should you build it?
NEED A CLEARER CALL?
Run an Investment Memo to get a structured Go / No-Go verdict, competitor landscape, unit economics, and a 90-day validation roadmap for this opportunity.
Generate an investment memoWhat this score means
This idea scores in the upper-middle range of opportunities surfaced by MonetScope, with a validation sub-score of 8/10 against 3 independently sourced evidence signals. A "promising" rating usually indicates a real pain has been detected and discussed in the open, but the pipeline did not find enough signal to flag it as urgent or high-frequency. These opportunities can still produce excellent businesses — they often correspond to "boring" problems that established players have ignored — but the founder should expect a longer customer-development cycle to confirm willingness to pay.
Why this matters for SaaS founders
It sits at the intersection of "analytics", "healthcare", "mobile-app", which makes it relevant to a specific subset of founders rather than a generic horizontal opportunity. SaaS opportunities at this stage tend to win on the strength of their initial wedge — a single workflow that the target user runs every week, where the existing solution is either spreadsheets, a clunky incumbent feature, or a manual process they hate. The build cost is moderate; the distribution cost is everything. The MonetScope pipeline surfaces this category alongside other saas signals, which is why it appears here rather than in a generic "trending ideas" feed.
Scores are derived from real forum discussions across Reddit, Hacker News and X, weighted by evidence volume and signal quality. How scoring works
Frequently asked questions
Is "ADHDMedTracker: Tolerance & Efficacy Tracking Protocol for Treatment-Resistant Adults" a real validated startup idea or just an AI-generated suggestion?
MonetScope does not generate ideas from a language model's imagination. Every opportunity on this site is anchored to specific source posts and comments from real public discussions — typically on Reddit, Hacker News, or X — where actual users describe the pain in their own words. The AI's role is structuring, scoring, and grouping those signals into a navigable opportunity, not inventing the problem.
How recent is the underlying data for analytics?
MonetScope's spider pipeline runs continuously and surfaces opportunities as new evidence accumulates. The "Updated" date in the header reflects the most recent re-scoring of this specific opportunity. Most saas opportunities visible in the public catalog draw from discussions in the last 30-60 days; older signals are de-prioritized because user pain shifts faster than most founders assume.
What's the difference between "overall score" and "validation score"?
Overall score is a composite across six dimensions — pain, urgency, willingness to pay, market size, defensibility, and execution ease — designed to give a single number for triage. Validation score is narrower: it asks "how cleanly does the same signal repeat across independent sources?" An opportunity can score high on overall but lower on validation when one or two large discussions dominate the evidence; conversely, validation can be high on a smaller-overall idea where the signal is consistent but the addressable market is modest.